

Douglas J Conrad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6866612/publications.pdf>

Version: 2024-02-01

34
papers

1,377
citations

430874

18
h-index

434195

31
g-index

34
all docs

34
docs citations

34
times ranked

2038
citing authors

#	ARTICLE	IF	CITATIONS
1	Bone Marrow Transplantation Rescues Monocyte Recruitment Defect and Improves Cystic Fibrosis in Mice. <i>Journal of Immunology</i> , 2022, 208, 745-752.	0.8	7
2	Complex and unexpected outcomes of antibiotic therapy against a polymicrobial infection. <i>ISME Journal</i> , 2022, 16, 2065-2075.	9.8	11
3	Multi-dimensional clinical phenotyping of a national cohort of adult cystic fibrosis patients. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 91-96.	0.7	8
4	Automated CT Staging of Chronic Obstructive Pulmonary Disease Severity for Predicting Disease Progression and Mortality with a Deep Learning Convolutional Neural Network. <i>Radiology: Cardiothoracic Imaging</i> , 2021, 3, e200477.	2.5	22
5	Plasmonic Sensing Studies of a Gas-Phase Cystic Fibrosis Marker in Moisture Laden Air. <i>Sensors</i> , 2021, 21, 3776.	3.8	3
6	Tensin 1 (<i>TNS1</i>) is a modifier gene for low body mass index (BMI) in homozygous [<i>F508del</i>]CFTR patients. <i>Physiological Reports</i> , 2021, 9, e14886.	1.7	0
7	Draft Genome Sequence of the Multidrug-Resistant Strain <i>Pseudomonas aeruginosa</i> PA291, Isolated from Cystic Fibrosis Sputum. <i>Microbiology Resource Announcements</i> , 2021, 10, e0057221.	0.6	0
8	Multi-Omics Study of Keystone Species in a Cystic Fibrosis Microbiome. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12050.	4.1	14
9	Safety, Tolerability, and Effects of Sodium Bicarbonate Inhalation in Cystic Fibrosis. <i>Clinical Drug Investigation</i> , 2020, 40, 105-117.	2.2	20
10	High-Resolution Longitudinal Dynamics of the Cystic Fibrosis Sputum Microbiome and Metabolome through Antibiotic Therapy. <i>MSystems</i> , 2020, 5, .	3.8	47
11	Optimizing sequencing protocols for leaderboard metagenomics by combining long and short reads. <i>Genome Biology</i> , 2019, 20, 226.	8.8	47
12	Molecular and Microbial Microenvironments in Chronically Diseased Lungs Associated with Cystic Fibrosis. <i>MSystems</i> , 2019, 4, .	3.8	23
13	Cystic Fibrosis Rapid Response: Translating Multi-omics Data into Clinically Relevant Information. <i>MBio</i> , 2019, 10, .	4.1	20
14	Niche partitioning of a pathogenic microbiome driven by chemical gradients. <i>Science Advances</i> , 2018, 4, eaau1908.	10.3	40
15	Three-Dimensional Microbiome and Metabolome Cartography of a Diseased Human Lung. <i>Cell Host and Microbe</i> , 2017, 22, 705-716.e4.	11.0	111
16	Median regression spline modeling of longitudinal FEV1 measurements in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) patients. <i>PLoS ONE</i> , 2017, 12, e0190061.	2.5	6
17	Smartphone-Based pH Sensor for Home Monitoring of Pulmonary Exacerbations in Cystic Fibrosis. <i>Sensors</i> , 2017, 17, 1245.	3.8	13
18	Ecological networking of cystic fibrosis lung infections. <i>Npj Biofilms and Microbiomes</i> , 2016, 2, 4.	6.4	77

#	ARTICLE	IF	CITATIONS
19	A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. <i>Journal of Cystic Fibrosis</i> , 2016, 15, 495-502.	0.7	59
20	Microbial, host and xenobiotic diversity in the cystic fibrosis sputum metabolome. <i>ISME Journal</i> , 2016, 10, 1483-1498.	9.8	88
21	Using Cystic Fibrosis Therapies for Non-Cystic Fibrosis Bronchiectasis. <i>Clinics in Chest Medicine</i> , 2016, 37, 139-146.	2.1	11
22	Characterizing Lung Disease in Cystic Fibrosis with Magnetic Resonance Imaging and Airway Physiology. <i>PLoS ONE</i> , 2016, 11, e0157177.	2.5	7
23	Metabolomics of pulmonary exacerbations reveals the personalized nature of cystic fibrosis disease. <i>PeerJ</i> , 2016, 4, e2174.	2.0	45
24	Multidimensional Clinical Phenotyping of an Adult Cystic Fibrosis Patient Population. <i>PLoS ONE</i> , 2015, 10, e0122705.	2.5	19
25	A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. <i>Journal of Cystic Fibrosis</i> , 2015, 14, 507-514.	0.7	62
26	Mass spectral similarity for untargeted metabolomics data analysis of complex mixtures. <i>International Journal of Mass Spectrometry</i> , 2015, 377, 719-727.	1.5	90
27	Metabolomics by mass spectrometry based molecular networking and spatial mapping. <i>FASEB Journal</i> , 2015, 29, 369.1.	0.5	0
28	Breath gas metabolites and bacterial metagenomes from cystic fibrosis airways indicate active pH neutral 2,3-butanedione fermentation. <i>ISME Journal</i> , 2014, 8, 1247-1258.	9.8	114
29	Metagenomics and metatranscriptomics: Windows on CF-associated viral and microbial communities. <i>Journal of Cystic Fibrosis</i> , 2013, 12, 154-164.	0.7	142
30	Cystic Fibrosis Therapy: A Community Ecology Perspective. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2013, 48, 150-156.	2.9	94
31	Frequency of mitochondrial 12S ribosomal RNA variants in an adult cystic fibrosis population. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 1095-1102.	1.5	19
32	Regulation of Human 12/15-Lipoxygenase by Stat6-Dependent Transcription. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2000, 22, 226-234.	2.9	53
33	The arachidonate 12/15 lipoxygenases. <i>Clinical Reviews in Allergy and Immunology</i> , 1999, 17, 71-89.	6.5	86
34	Microgranulomatous aspergillosis after shoveling wood chips: Report of a fatal outcome in a patient with chronic granulomatous disease. <i>American Journal of Industrial Medicine</i> , 1992, 22, 411-418.	2.1	19